Anavex Life Sciences Corp (AVXL)

[Investor2014]

As a long term investor, this update is good enough for me.

Some will be pleased to learn and IND has been filed for Rett.

Others will be pleased to learn that comprehensive fluid-based biomarkers and multimodal neuroimaging will use in the trial.

-- The Company filed an IND for ANAVEX(R)2-73 in Rett syndrome, for which
the Company received orphan drug designation by the FDA, and is expecting
feedback from the FDA to finalize the clinical trial protocol for this
study. As start-up activities with clinical trial sites have been
underway, the Company anticipates dosing the first patient in due course
following FDA approval of the IND.

-- With the integration of genome sequencing information from
ANAVEX(R)2-73-treated patients, the Company is now able to enhance the
planned Alzheimer's Phase 2/3 study. It is expected that incorporating
this novel precision medicine approach as well as including comprehensive
fluid-based biomarkers and multimodal neuroimaging, will enable a more
robust regulatory submission, anticipated within the upcoming quarter.
The randomized, double-blind, placebo-controlled study will be aimed at
evaluating the safety, tolerability and efficacy of ANAVEX(R)2-73 in
Alzheimer's disease patients and will be conducted in both Australia and
North America. Further details of the study will be shared in upcoming
announcements.

-- Due the strength of the preclinical Parkinson's disease data on
ANAVEX(R)2-73 from a collaboration with Michael J. Fox Foundation, Anavex
plans to file an upcoming clinical trial application (CTA) with European
regulatory authorities to conduct a Phase 2 trial for ANAVEX(R)2-73 in
Parkinson's disease patients.